ReviewCancers2021
Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Safety assessment of autologous ovarian tissue cryopreservation and transplantation in cancer patients: an updated review.Journal of ovarian research · 2026Review
- Microfluidics for Blood Disorders and Hematological Disease Monitoring and Modeling.International journal of molecular sciences · 2026Review
- A context-aware interpretive framework for lymphocyte immunophenotyping by flow cytometry.Frontiers in immunology · 2026Article
- Validation of an Adapted NGS-Based Clonality Assay for MRD Monitoring in B-ALL Using Archived and Follow-Up Samples.EJHaem · 2025Article
- The role of advanced diagnostics on precision medicine in hemato oncology.Discover oncology · 2025Review
- Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer.Translational lung cancer research · 2025Review
- Study on the impact of CD4Clinical and experimental medicine · 2025Article
- Clinical significance of CD45 and CD200 expression in newly diagnosed multiple myeloma patients.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- [Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Detection of acute myeloid leukemia and remission states using heterogeneous flow cytometry data.Frontiers in oncology · 2025Article
- Flow cytometric analysis for Ki67 assessment in formalin-fixed paraffin-embedded breast cancer tissue.BMC biology · 2024Article
- MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.Current hematologic malignancy reports · 2024Review
- Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.Clinical and experimental medicine · 2024Article
- Toward Standardization of Flow-Cytometric Immunophenotyping for the Diagnosis and Monitoring of Hematologic Malignancies.Annals of laboratory medicine · 2024Article
- Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea.Annals of laboratory medicine · 2024Article
- Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.International journal of molecular sciences · 2024Review
- Raman Spectroscopy as a Research and Diagnostic Tool in Clinical Hematology and Hematooncology.International journal of molecular sciences · 2024Review
- Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of Minimal Residual Disease (MRD) has progressively become a keystone in the clinical management of hematologic malignancies, enabling valuable post-therapy risk stratifications and guiding risk-adapted therapeutic approaches. However, specific prognostic values of MRD in different hematological settings, as well as its appropriate clinical uses (basically, when to measure it and how to deal with different MRD levels), still need further investigations, aiming to improve standardization and harmonization of MRD monitoring protocols and MRD-driven therapeutic strategies. Currently, MRD measurement in hematological neoplasms with bone marrow involvement is based on advanced highly sensitive methods, able to detect either specific genetic abnormalities (by PCR-based techniques and next-generation sequencing) or tumor-associated immunophenotypic profiles (by multiparametric flow cytometry, MFC). In this review, we focus on the growing clinical role for MFC-MRD diagnostics in hematological malignancies-from acute myeloid and lymphoblastic leukemias (AML, B-ALL and T-ALL) to chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)-providing a comparative overview on technical aspects, clinical implications, advantages and pitfalls of MFC-MRD monitoring in different clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.